A5037740266- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Immunodeficiency and Autoimmune Disorders
- Acute Myeloid Leukemia Research
- Immune Cell Function and Interaction
- Chronic Myeloid Leukemia Treatments
- Glycosylation and Glycoproteins Research
- CAR-T cell therapy research
- Cancer-related Molecular Pathways
- CNS Lymphoma Diagnosis and Treatment
- MicroRNA in disease regulation
- Circular RNAs in diseases
- Advanced Breast Cancer Therapies
- Cancer-related molecular mechanisms research
- Monoclonal and Polyclonal Antibodies Research
- Genomic variations and chromosomal abnormalities
- RNA modifications and cancer
- Lung Cancer Treatments and Mutations
- T-cell and Retrovirus Studies
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Galectins and Cancer Biology
- Acute Lymphoblastic Leukemia research
- Eosinophilic Disorders and Syndromes
Nanjing Medical University
2016-2025
Jiangsu Province Hospital
2016-2025
State Key Laboratory of Food Science and Technology
2025
Jiangnan University
2025
Chinese Academy of Fishery Sciences
2024-2025
Qingdao Municipal Hospital
2022-2025
Qingdao University
2022-2025
Second Affiliated Hospital of Soochow University
2025
Soochow University
2023-2025
Chinese People's Liberation Army
2025
Gendicine (recombinant human p53 adenovirus), developed by Shenzhen SiBiono GeneTech Co. Ltd., was approved in 2003 the China Food and Drug Administration (CFDA) as a first-in-class gene therapy product to treat head neck cancer, entered commercial market 2004. is biological that delivered via minimally invasive intratumoral injection, well intracavity or intravascular infusion. The wild-type (wt) protein expressed Gendicine-transduced cells tumor suppressor activated cellular stress,...
Abstract Purpose: Mantle-cell lymphoma (MCL) is an incurable mature B-cell neoplasm with high initial response rates followed almost invariably by relapse. Prognosis for patients following relapse poor, and treatment choices are limited. We evaluated the efficacy safety of zanubrutinib, investigational selective Bruton's tyrosine kinase (BTK) inhibitor. Patients Methods: relapsed/refractory MCL were enrolled in this ongoing phase II, single-arm, open-label study, treated oral zanubrutinib...
Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, approved patients with MCL who have received ≥1 prior therapy. We report the long-term safety and efficacy results from multicenter, open-label, phase 2 registration trial of zanubrutinib. Patients (n = 86) oral zanubrutinib 160 mg twice daily. The primary endpoint was overall response rate (ORR), assessed per Lugano...
Abstract Background Bruton tyrosine kinase (BTK) inhibitors have demonstrated a high degree of efficacy in the treatment B cell malignancies characterized by constitutive receptor activation, including chronic lymphocytic leukemia/small lymphoma (CLL/SLL). Methods The and safety zanubrutinib, an investigational highly selective BTK inhibitor, was evaluated this single-arm, phase 2 study Chinese patients with relapsed/refractory CLL/SLL. primary endpoint overall response rate as assessed...
Epstein-Barr virus (EBV) positive diffuse large B-cell lymphoma (DLBCL) of the elderly is defined as patients older than 50 years alone. However, recent studies showed young with sound immune status could also be affected. In this study, we investigated clinical features and outcomes EBV DLBCL in different age groups using EBER cut-off values. The prevalence was 14.0% (35/250) 10.4% (26/250) for 20% 50%, respectively. With both values, shared many unfavorable prognostic characteristics,...
Circular RNAs (circRNAs), a novel family of non-coding RNAs, play crucial roles in cancer progression. While the existing research focuses on nuclear genome-derived (nu)-circRNAs, biological and clinical characteristics mitochondrial (mt)-circRNAs remain largely unknown, especially chronic lymphocytic leukemia (CLL). In this study, we attempted to identify mc-COX2 (mitochondrial circRNAs [mc]), one mt-circRNAs that can be involved CLL were found highly expressed plasma exosomes patients. The...
Abstract This study (ORIENT-4) aimed to assess the efficacy and safety of sintilimab, a humanized anti-PD-1 antibody, in patients with relapsed/refractory extranodal NK/T cell lymphoma (r/r ENKTL). ORIENT-4 is multicenter, single-arm, phase 2 clinical trial (NCT03228836). Patients r/r ENKTL who failed at least one asparaginase-based regimen were enrolled receive sintilimab 200 mg intravenously every 3 weeks for up 24 months. The primary endpoint was objective response rate (ORR) based on...
Abstract Orelabrutinib is a novel, small molecule, selective irreversible Bruton's tyrosine kinase inhibitor. The aim of this study was to evaluate the efficacy and safety in patients with refractory or relapsed chronic lymphocytic leukemia (CLL)/small lymphoma (SLL). This single‐arm, multi‐center, open‐label, phase 2 80 eligible Chinese patients, who were treated monotherapy orelabrutinib at 150 mg once daily. Overall response rate evaluated by an independent review committee primary...
Abstract Anti-PD-1 antibodies are a favorable treatment for relapsed or refractory extranodal natural killer T cell lymphoma (RR-ENKTL), however, the complete response (CR) rate and duration of (DOR) need to be improved. This phase 1b/2 study investigated safety efficacy sintilimab, fully human anti-PD-1 antibody, plus chidamide, an oral subtype-selective histone deacetylase inhibitor in 38 patients with RR-ENKTL. Expected objective (ORR) combination was 80%. Patients received escalating...
The treatment of gastric cancer remains highly challenging, particularly in cases unresectable locally advanced or metastatic disease. Although chemotherapy and immunotherapy have shown some efficacy such patients, significant limitations persist extending survival enhancing safety. To address these challenges, we designed an innovative first-line quadruple conversion therapy regimen that integrates a programmed cell death protein 1 (PD-1) inhibitor with chemotherapy, successfully...
Cyclooxygenase-2 (COX-2) plays an important role in the carcinogenesis and progression of gastric cancer. It has been demonstrated that COX-2 overexpression depends on different cellular pathways, involving both transcriptional post-transcriptional regulation. MicroRNAs (miRNAs) are small, noncoding RNAs function as regulators. Here, we characterize miR-101 expression its regulation expression, which turn, will provide us with additional insights into potential therapeutic benefits exogenous...
Cisplatin is a cytotoxic platinum compound that triggers DNA crosslinking induced cell death, and one of the reference drugs used in treatment several types human cancers including gastric cancer. However, intrinsic or acquired drug resistance to cisplatin very common, leading failure. We have recently shown reduced expression base excision repair protein XRCC1 (X-ray cross complementing group1) cancerous tissues correlates with significant survival benefit from adjuvant first-line...
Abstract Chronic activation of the Bruton’s tyrosine kinase (BTK)-mediated B-cell receptor (BCR) signaling is a hallmark many lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and diffuse large lymphoma (DLBCL). Ibrutinib, an FDA approved, orally administered BTK inhibitor, has demonstrated high response rates, however, complete responses are infrequent acquired resistance to inhibition can emerge. In this study, we generated ibrutinib-resistant (IB-R) cell lines by...
Circular RNAs (circRNAs) have recently been reported to play crucial roles in various regulatory processes and involved cancer onset progression. However, the potential mechanism of circRNAs chronic lymphocytic leukemia (CLL) remains largely unknown. Here, we observed hsa_circ_0132266 (circ_0132266), a circRNA significantly decreased peripheral blood mononuclear cells (PBMCs) CLL patients compared with healthy donors, could act as an endogenous sponge hsa-miR-337-3p (miR-337-3p) regulate its...
Rationale: Stem cells self-organize to form organoids that generate mini-organs resemble the physiologically-developed ones.The mechanism by which stem acquire initial potential for generating remains elusive.Here we used skin as an example study how mechanical force drives epidermal-dermal interaction potentiates regenerate hair follicles.Methods: Live imaging analysis, single-cell RNA-sequencing and immunofluorescence were analyze contractile of dermal in organoids.Bulk calcium probe...